Q3 2024 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2024-11-14 · accession 0001493152-24-045811
$599.6M
Reported value
44
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW HEALTH INC | $179.4M | 29.9% | 3,990,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $53.3M | 8.89% | 2,280,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $43.7M | 7.29% | 5,025,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $30.9M | 5.16% | 1,255,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $27.0M | 4.51% | 8,770,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $26.2M | 4.37% | 500,000 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $23.0M | 3.83% | 395,276 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $18.1M | 3.02% | 1,237,500 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $17.0M | 2.83% | 1,698,142 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $16.7M | 2.78% | 2,780,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $13.9M | 2.33% | 522,500 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $11.8M | 1.97% | 541,437 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC' | $11.2M | 1.87% | 1,320,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $9.7M | 1.62% | 85,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $9.4M | 1.57% | 420,000 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $9.3M | 1.56% | 1,893,660 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $8.6M | 1.43% | 2,567,990 | Common | SOLE |
| 09075X108 | — | BIODESIX INC | $7.0M | 1.16% | 3,815,000 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS | $6.7M | 1.11% | 820,202 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $6.6M | 1.11% | 353,500 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $6.6M | 1.10% | 250,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $6.5M | 1.09% | 64,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $5.6M | 0.93% | 335,000 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $5.1M | 0.86% | 404,100 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $4.7M | 0.79% | 105,000 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $4.2M | 0.70% | 8,000,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $4.0M | 0.66% | 75,300 | Common | SOLE |
| 48576UAA4 | — | KARYOPHARM THERAPEUTICS INC | $4.0M | 0.66% | 6,000,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $3.7M | 0.62% | 3,665,010 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $3.6M | 0.59% | 967,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $3.1M | 0.51% | 1,681,154 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $2.3M | 0.38% | 466,563 | Common | SOLE |
| 14888U101 | CPRX | CATALYST PHARMACEUTICALS INC | $2.2M | 0.37% | 112,500 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $2.1M | 0.35% | 800,000 | Common | SOLE |
| 55083R104 | — | LYELL IMMUNOPHARMA INC | $1.9M | 0.32% | 1,395,000 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $1.6M | 0.26% | 2,407,600 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $1.6M | 0.26% | 480,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $1.5M | 0.26% | 179,200 | Common | SOLE |
| 761330109 | RVNCEUR | REVANCE THERAPEUTICS INC | $1.4M | 0.24% | 275,000 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $1.4M | 0.23% | 654,943 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $919,600 | 0.15% | 440,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $839,950 | 0.14% | 535,000 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $832,500 | 0.14% | 375,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $285,273 | 0.05% | 110,571 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.